RxDoctor Payments Data

Christopher Lucas, DO

Internal Medicine · Paoli, PANPI 1538136387

Payments from drug & device makers

$592in general payments, 2019–2025

Across 36 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$217
  • Amgen$115
  • Kowa Pharmaceuticals America, Inc.$82
  • Novo Nordisk$50
  • Boehringer Ingelheim$45
  • IBSA Pharma Inc.$34
  • plus $49 from 3 others

What the payments were for

  • Food & beverage$58699%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$592 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$132,004
Medicare patients
242
Services billed
1,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin100$117,441
EliquisApixaban62$71,751
OzempicSemaglutide44$42,721
XareltoRivaroxaban16$25,863
JanuviaSitagliptin Phosphate11$15,528
XanaxAlprazolam16$12,619
CrestorRosuvastatin Calcium12$9,019
SynthroidLevothyroxine Sodium55$7,424
Praluent PenAlirocumab13$6,114
Breo ElliptaFluticasone/Vilanterol14$5,530
VascepaIcosapent Ethyl16$5,477
Rosuvastatin Calcium274$3,053
Atorvastatin Calcium239$2,673
Olmesartan Medoxomil66$2,589
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$2,238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$45$117,441100 claims
PfizerEliquis, Paxlovid$18$73,18190 claims
Novo NordiskOzempic$50$42,72144 claims
Johnson & JohnsonXarelto$17$25,86316 claims
AstraZenecaCrestor$217$9,01912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Paoli

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →